You are here: Industry Insights > Clinigen

News List

Clinigen's ALS therapy bags US orphan status pharmatimes
July 14, 2020
ALS is a severe, neurodegenerative disease which affects motor neurons leading to progressive muscle weakness, paralysis and ultimately death within a median time of two to four years from disease onset.
Clinigen Launches Managed Access Program for Progenics Pharmaceuticals for AZEDRA® Outside the US b3cnewswire
October 11, 2019
Clinigen Group plc, the global pharmaceutical and services company, has launched a Managed Access Program for Progenics Pharmaceuticals, Inc. ...
Clinigen to distribute Etopophos, Vepesid in Australia and NZ biospectrumasia
September 03, 2019
Exclusive distribution agreement with CHEPLAPHARM for an essential medicine to treat priority diseases like Small Cell Lung Cancer, Hodgkin's Disease, Malignant (non-Hodgkin's) lymphomas, Acute non-lymphocytic leukaemia and Testicular tumours
Clinigen obtains marketing authorisations for Melatonin pharmaceutical-technology
June 28, 2019
Clinigen Group has secured marketing authorisations from the Medicines and Healthcare Products Regulatory Agency (MHRA) for Melatonin 1mg/ml oral solution and Melatonin 3mg film-coated tablets.
Clinigen Broadens Partnership with Accord Healthcare to Supply and Distribute Cardioxane® and Savene® in Poland b3cnewswire
June 24, 2019
Clinigen Group announces that its Commercial Medicines business has signed an exclusive agreement with Accord Healthcare (‘Accord’) to supply and distribute Clinigen’s speciality medicines, Cardioxane® and Savene® in Poland.
Clinigen Completes Acquisition of US Rights to Proleukin firstwordpharma
April 04, 2019
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company……
Clinigen Extends Exclusive European Clinical Trial Sourcing and Supply Agreement with Accord Healthcare b3cnewswire
January 11, 2019
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Trial Service (‘CTS’) business has extended its exclusive European clinical trial supply agreement with.....
Clinigen buys global rights to Horizon’s Imukin pharmatimes
July 27, 2018
The UK’s Clinigen Group has bought global rights to rare disease therapy Imukin from Horizon Pharma, for an undisclosed amount.
Clinigen Signs Exclusive Supply & Distribution Agreement with Lukare for Elliotts B® Solution b3cnewswire
July 04, 2018
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an exclusive agreement with Lukare Medical (‘Lukare’) to manage the supply and distribution of Elliotts B® Solution.
Clinigen Signs Exclusive Supply & Distribution Agreement with Lukare for Elliotts B® Solution b3cnewswire
June 20, 2018
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an exclusive agreement with Lukare Medical (‘Lukare’) to manage the supply and distribution of Elliotts B® Solution.

Previous page 1 2 Next page